Goldman Sachs analyst Salveen Richter has maintained their neutral stance on IONS stock, giving a Hold rating on September 25.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Salveen Richter’s rating is based on Ionis Pharmaceuticals’ strategic advancements and potential market opportunities. The company has optimized its antisense oligonucleotide technology, which has shown promising results in recent clinical trials, particularly in treating severe hypertriglyceridemia. This technological enhancement positions Ionis to capitalize on its pipeline opportunities, as evidenced by the anticipated launch of Tryngolza and its projected peak sales.
Additionally, Ionis is preparing to expand its commercial infrastructure to support upcoming product launches, such as Dawnzera for hereditary angioedema and zilganersen for Alexander disease. However, the company faces competitive challenges in the cardiovascular and ATTR-cardiomyopathy markets, which may impact its growth prospects. These factors contribute to the Hold rating, reflecting a balanced view of the company’s potential and the risks involved.